Is the current product safety assessment paradigm protective for epigenetic mechanisms?

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 3, 2012, Pages 207-214

  Alyea, Rebecca A ^a   Moore, Nigel P ^b   LeBaron, Matthew J ^a   Gollapudi, B Bhaskar ^a   Rasoulpour, Reza J ^a  

^a DOW CHEMICAL COMPANY   (United States)

^b DOW EUROPE GMBH   (Switzerland)

Author keywords

1,3 butadiene; Arsenic; Diethylstilbestrol; Epigenetic mechanisms; Epigenetics in toxicology; Product safety assessment

Indexed keywords

1,3 BUTADIENE; ARSENIC; DIETHYLSTILBESTROL;

ADVERSE OUTCOME; ARTICLE; DNA METHYLATION; DOSE RESPONSE; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE CONTROL; HAZARD ASSESSMENT; HISTONE METHYLATION; HUMAN; INTOXICATION; LOWEST OBSERVED ADVERSE EFFECT LEVEL; NO OBSERVED ADVERSE EFFECT LEVEL; NONHUMAN; PERINATAL DRUG EXPOSURE; PHENOTYPE; PRENATAL EXPOSURE; PRODUCT RECOVERY; PROTEIN EXPRESSION; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; TOXICITY TESTING; TOXICOGENETICS;

EID: 84870672748     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.05.005     Document Type: Article

References (35)

1. Anway, M. D., Cupp, A. S., Uzumcu, M., & Skinner,M. K. (2005). Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science, 308, 1466-1469.
2. Barker, D. J., Gluckman, P. D., Godfrey, K. M., Harding, J. E., Owens, J. A., & Robinson, J. S. (1993). Fetal nutrition and cardiovascular disease in adult life. Lancet, 341(8850), 938-941.
3. Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B., et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Critical Reviews in Toxicology, 38(2), 87-96, http://dx.doi.org/10.1080/10408440701749421 790482621 [pii].
4. Bromer, J. G., Wu, J., Zhou, Y., & Taylor, H. S. (2009). Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: An epigenetic mechanism for altered developmental programming. Endocrinology, 150(7), 3376-3382, http://dx.doi.org/10.1210/en.2009-0071.
5. Burdge, G. C., Hoile, S. P., Uller, T., et al. (2011). Progressive, transgenerational changes in offspring phenotype and epigenotype following nutritional transition. PLoS One, 6(11), e28282, http://dx.doi.org/10.1371/journal.pone.0028282.
6. Chen, H., Li, S., Liu, J., Diwan, B. A., Barrett, J. C., & Waalkes, M. P. (2004). Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: Implications for arsenic hepatocarcinogenesis. Carcinogenesis, 25(9), 1779-1786, http://dx.doi.org/10.1093/carcin/bgh161.
7. Doherty, L. F., Bromer, J. G., Zhou, Y., Aldad, T. S., & Taylor, H. S. (2010). In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer. Hormones & cancer, 1(3), 146-155, http://dx.doi.org/10.1007/s12672-010-0015-9.
8. Dragani, T. A., Manenti, G., Gariboldi, M., De Gregorio, L., & Pierotti, M. A. (1995). Genetics of liver tumor susceptibility in mice. Toxicology Letters, 82-83, 613-619.
9. Goodman, J. I., Augustine, K. A., Cunnningham, M. L., et al. (2010). What do we need to know prior to thinking about incorporating an epigenetic evaluation into safety assessments? Toxicological sciences: An official journal of the Society of Toxicology, 116(2), 375-381, http://dx.doi.org/10.1093/toxsci/kfq133.
10. Hales, C. N., & Barker, D. J. (2001). The thrifty phenotype hypothesis. British Medical Bulletin, 60, 5-20.
11. Haseman, J. K., Crawford, D. D., Huff, J. E., Boorman, G. A., & McConnell, E. E. (1984). Results from 86 two-year carcinogenicity studies conducted by the National Toxicology Program. Journal of Toxicology and Environmental Health, 14(5-6), 621-639, http://dx.doi.org/10.1080/15287398409530613.
12. Haseman, J. K., Hailey, J. R., & Morris, R. W. (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicologic Pathology, 26(3), 428-441.
13. Holsapple, M. P., Pitot, H. C., Cohen, S. M., et al. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicological sciences: an official journal of the Society of Toxicology, 89(1), 51-56, http://dx.doi.org/10.1093/toxsci/kfj001 (kfj001 [pii]).
14. Hoover, R. N., Hyer, M., Pfeiffer, R. M., et al. (2011). Adverse health outcomes in women exposed in utero to diethylstilbestrol. The New England Journal of Medicine, 365(14), 1304-1314, http://dx.doi.org/10.1056/NEJMoa1013961.
15. Kirchner, S., Kieu, T., Chow, C., Casey, S., & Blumberg, B. (2010). Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Molecular Endocrinology, 24(3), 526-539, http://dx.doi.org/ 10.1210/me.2009-0261.
16. Koc, H., Tretyakova, N. Y.,Walker, V. E., Henderson, R. F., & Swenberg, J. A. (1999). Molecular dosimetry of N-7 guanine adduct formation in mice and rats exposed to 1,3-butadiene. Chemical Research in Toxicology, 12(7), 566-574, http://dx.doi.org/10.1021/tx980265f.
17. Koturbash, I., Scherhag, A., Sorrentino, J., et al. (2011). Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. Toxicological sciences: an official journal of the Society of Toxicology, 122(2), 448-456, http://dx.doi.org/10.1093/toxsci/kfr133.
18. Koturbash, I., Scherhag, A., Sorrentino, J., et al. (2011). Epigenetic alterations in liver of C57BL/6J mice after short-term inhalational exposure to 1,3-butadiene. Environmental Health Perspectives, 119(5), 635-640, http://dx.doi.org/10.1289/ehp. 1002910.
19. LeBaron, M. J., Rasoulpour, R. J., Klapacz, J., Ellis-Hutchings, R. G., Hollnagel, H. M., & Gollapudi, B. B. (2010). Epigenetics and chemical safety assessment. Mutation Research, 705(2), 83-95, http://dx.doi.org/10.1016/j.mrrev.2010.04.003.
20. Li, S., Hansman, R., Newbold, R., Davis, B., McLachlan, J. A., & Barrett, J. C. (2003). Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Molecular Carcinogenesis, 38(2), 78-84, http://dx.doi.org/10.1002/mc.10147.
21. Li, S., Washburn, K. A., Moore, R., et al. (1997). Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Research, 57(19), 4356-4359.
22. Miranda, T. B., & Jones, P. A. (2007). DNA methylation: The nuts and bolts of repression. Journal of Cellular Physiology, 213(2), 384-390, http://dx.doi.org/10.1002/jcp. 21224.
23. Newbold, R. R., Banks, E. P., Bullock, B., & Jefferson, W. N. (2001). Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Research, 61(11), 4325-4328.
24. Newbold, R. R., Bullock, B. C., & McLachlan, J. A. (1990). Uterine adenocarcinoma in mice following developmental treatment with estrogens: A model for hormonal carcinogenesis. Cancer Research, 50(23), 7677-7681.
25. Newbold, R. R., Hanson, R. B., Jefferson, W. N., Bullock, B. C., Haseman, J., & McLachlan, J. A. (1998). Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis, 19(9), 1655-1663.
26. NTP (1984). NTP toxicology and carcinogenesis studies of 1,3-butadiene (CAS no. 106-99-0) in B6C3F1 mice (inhalation studies). National Toxicology Program Technical Report Series, 288, 1-111.
27. NTP (1993). NTP toxicology and carcinogenesis studies of 1,3-butadiene (CAS no. 106-99-0) in B6C3F1 mice (inhalation studies). National Toxicology Program Technical Report Series, 434, 1-389.
28. Rasoulpour, R. J., LeBaron, M. J., Ellis-Hutchings, R. G., Klapacz, J., & Gollapudi, B. B. (2011). Epigenetic screening in product safety assessment: Are we there yet? Toxicology Mechanisms and Methods, 21(4), 298-311, http://dx.doi.org/10.3109/15376516.2011.557883.
29. Skinner, M. K. (2008). What is an epigenetic transgenerational phenotype? F3 or F2. Reproductive Toxicology, 25(1), 2-6, http://dx.doi.org/10.1016/j.reprotox.2007.09.001.
30. Slikker, W., Jr., Andersen, M. E., Bogdanffy, M. S., et al. (2004). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicology and Applied Pharmacology, 201(3), 226-294, http://dx.doi.org/10.1016/j.taap.2004.06.027 (S0041-008X(04) 00316-3 [pii]).
31. Smallwood, S. A., & Kelsey, G. (2012). De novo DNAmethylation: A germ cell perspective. Trends in genetics: TIG, 28(1), 33-42, http://dx.doi.org/10.1016/j.tig.2011.09.004.
32. Tang, W. Y., Newbold, R., Mardilovich, K., et al. (2008). Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology, 149(12), 5922-5931, http://dx.doi.org/10.1210/en.2008-0682.
33. Tokar, E. J., Diwan, B. A., Ward, J. M., Delker, D. A., & Waalkes, M. P. (2011). Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 mice. Toxicological sciences: an official journal of the Society of Toxicology, 119(1), 73-83, http://dx.doi.org/10.1093/toxsci/kfq315.
34. Waalkes, M. P., Ward, J. M., & Diwan, B. A. (2004). Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: Promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. Carcinogenesis, 25(1), 133-141, http://dx.doi.org/10.1093/carcin/bgg181.
35. Xie, Y., Liu, J., Benbrahim-Tallaa, L., et al. (2007). Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology, 236(1-2), 7-15, http://dx.doi.org/10.1016/j.tox. 2007.03.021.